New hope for rare kidney cancer: targeted drug plus radiation may replace chemo

NCT ID NCT07498907

Not yet recruiting Disease control Sponsor: Peking University First Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new treatment for people with a rare cancer of the upper urinary tract (UTUC) that has spread beyond the kidney. Participants must have had surgery and cannot take standard chemo due to health reasons. They will receive either a targeted drug (disitamab vedotin) plus radiation or standard chemo. The goal is to see if the new combo helps prevent cancer from coming back longer.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UPPER TRACT UROTHELIAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

renal pelvis/ureter urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

UPPER TRACT UROTHELIAL CARCINOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Email: •••••@•••••

Locations

Peking University First Hospital

Beijing, China

Contact Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••